TIDMABDX
RNS Number : 4276H
Abingdon Health PLC
24 November 2022
Abingdon Health plc
("Abingdon" or "the Company")
Preliminary Results
York, U.K. 24 November 2022: Abingdon Health plc (AIM: ABDX), a
leading international developer and manufacturer of high quality,
rapid diagnostic tests, announces its preliminary results for the
year ended 30 June 2022.
Financial highlights
-- Revenue of GBP2.8m (2021: GBP11.6m) with prior year impacted by one-off COVID-19 revenues
-- Adjusted(*) EBITDA loss of GBP10.0m (2021: GBP3.3m loss) due
to significant increase in, and subsequent unwinding of,
operational headcount to meet anticipated COVID-19 demand which did
not come to fruition
-- Loss for the period of GBP21.3m (2021: GBP7.0m loss),
includes GBP7.2m impairment charge (2021: GBPnil)
-- Cash as at 30 June 2022: GBP2.4m (2021: GBP5.0m) and as at 31 October 2022 of GBP4.4m
-- Net cash outflow from operating activities of GBP7.7m (2021:
GBP12.9m), driven in part by a reduction year-on-year in
payables.
(*) Adjusted EBITDA stated before deduction of non-recurring
costs, impairment of intangibles and share based payment
Operational highlights (including post-period end)
-- Settlement agreement reached with the Department of Health
and Social Care ("DHSC") on the outstanding invoices payable by
DHSC for lateral flow tests and component stock, with GBP6.3m cash
being received in July 2022 in full settlement
-- Outcome of Judicial Review proceedings initiated by the Good
Law Project Limited ("GLP") against DHSC in which Abingdon was an
interested party ruled in favour of the DHSC on all grounds,
confirming that contract award decisions by DHSC, for the
development and manufacture of lateral flow test kits for COVID-19
antibodies by Abingdon, were lawful and complied with the
principles of public law
-- Launched e-commerce self-test site , marketing a range of
Abingdon Simply Test and other branded self-test products
-- Strategy focused on provision of Contract Development and
Manufacturing ("CDMO") services given anticipated growth in demand
within the lateral flow market
-- Strong pipeline of contract development, regulatory and technical transfer opportunities.
Chris Yates, Chief Executive Officer, Abingdon Health plc,
commented:
"The last two years within the lateral flow market have been
dominated by COVID-19 with little other contract development
activity being undertaken by customers or prospective customers. In
addition, a great deal of our own focus has been spent on
successfully resolving unwarranted legal challenges which were an
unwelcome distraction and a significant use of our time and
resources.
"It is pleasing to see the industry refocus on a much broader
range of applications of lateral flow technology in other health
and non-health areas. As a knowledge leader in lateral flow, and
with our comprehensive contract service offering, we believe we are
well-placed to support customers in bringing their products to
market and grow our business."
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross , Chief Financial Officer
Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Peter Steel, Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Marriage Mob: +44 (0)7980 541 893 / +44 (0)7867
Alice Woodings 984 082
+44 (0)7407 804 654
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018. Upon the publication of this announcement
via the Regulatory Information Service, this inside information is
now considered to be in the public domain.
About Abingdon Health plc
Abingdon Health is a world leading developer and manufacturer of
high-quality lateral flow rapid tests across all industry sectors,
including healthcare and COVID-19. Abingdon is the partner of
choice for a growing global customer base and takes projects from
initial concept through to routine and large-scale manufacturing
and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R) , a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
Chairman and CEO Joint Statement
Following a two-year period, where COVID-19 was the primary
focus of the lateral flow industry, we are now seeing growth in the
market across a broad range of other (non-COVID-19) applications,
driven by reduced barriers to adoption for the technology. In this
new environment, the Board has confidence that Abingdon Health's
knowledge leadership position in the lateral flow industry and the
development and manufacturing platform we have built will begin to
yield positive momentum and revenue growth. Our key objective is to
move the Company to positive cash flow.
This financial year was dominated by the continued impact of
COVID-19 on the lateral flow industry. There was limited
non-COVID-19 development activity in financial years 2021 and 2022
as most industry participants focused on developing and
manufacturing COVID-19 tests. Whilst we participated in providing
COVID-19 solutions through our commercial contracts with, inter
alia, Avacta, Vatic and BioSure; none of these activities yielded
material revenue traction beyond the successful transfer of all
three products to manufacture (technical transfer). We had
previously developed and manufactured 1 million COVID-19 antibody
tests for the Department of Health and Social Care (DHSC) in
FY2021. With COVID-19 strategies across the globe, China-aside,
transitioning towards treating COVID-19 as a seasonal disease, such
as flu, we are seeing a significant increase in engagement on
non-COVID-19 testing projects and believe that our expertise in the
lateral flow industry and the development and manufacturing
platform we have built will drive positive momentum and revenue
growth.
Strategy
Our mission at Abingdon is to improve life by making rapid
results accessible to all. We achieve this by supporting our
customers in developing and manufacturing lateral flow tests across
a range of sectors including human health, such as infectious
disease testing, animal health, plant pathogen and environmental
testing.
COVID-19 had a significant impact on lateral flow testing;
initially through widespread adoption of lateral flow testing
across many countries, including the UK. This has reduced the
"barriers to adoption" as many people are now extremely familiar
with lateral flow testing and "doing a lateral flow test" is now
part of the vernacular. There is increasing acceptance that lateral
flow testing is a viable, cost-effective alternative or complement
to laboratory testing. We strongly believe that this will drive the
increased adoption of lateral flow testing across a broad range of
applications and sectors
As a well-established knowledge leader within the area of
lateral flow testing, we are focused on providing a broad contract
development and manufacturing organisation ("CDMO") service to an
international customer base. We believe the CDMO business model,
well-established in the pharmaceutical industry, has direct
application to the medical diagnostics market and we offer our
customers a turn-key full-service offering in lateral flow which
includes research, development, scale-up, technical transfer,
manufacturing, regulatory approval, supply chain management, and
commercial support. Our long-term strategic objective is to become
the leading full-service CDMO in the lateral flow market.
In addition to our contract service business, we will continue
to consider options to develop, manufacture and commercialise , our
own products. We believe that COVID-19 is a catalyst for the
expansion of self-testing across a range of other clinical areas.
However, as set out below in the current economic environment our
focus is on driving our revenues, managing our costs and reaching a
cashflow positive position as quickly as possible. Therefore, we
will focus most of our team's efforts on driving CDMO revenues for
now rather than on significant internal product development. During
2022 we have built an ecommerce self-test site;
www.abingdonsimplytest.com ; launched in July 2022 which markets a
range of Abingdon Simply Test branded products and other branded
self-test products. We currently have a range of 14 products on
this newly launched site and we will continue to grow this in a
managed way. www.abingdonsimplytest.com also provides the
opportunity for our contract service customers to market their
products.
We strongly believe that we are at the start of a paradigm-shift
in the use and application of rapid testing across a wide range of
applications and that Abingdon Health is well positioned to support
customers in bringing new, innovative products to market across a
range of sectors.
Performance in year
Revenue for the full year was GBP2.8m (2021: GBP11.6m). In 2021
the financials were impacted significantly by revenue of GBP5.2m
from the Department for Health & Social Care ("DHSC") and a
one-off order for our nucleic acid lateral flow immunoassay called
PCRD. 2022 was a transition year as we moved the business away from
its focus on supporting COVID-19 solutions towards a normalised
business model where we operate as a CDMO offering our services to
customers across a wide range of sectors. We expect to see the
benefits of this transition in FY2023 and beyond, supported by the
forecast growth in the lateral flow market, which is expected to
grow to $13.4 billion by 2028, at a cumulative average growth rate
of 4.7% per annum (Source: Lateral Flow Assays Market Size &
Growth Analysis By 2030 (alliedmarketresearch.com) ).
2022 activity was dominated by COVID-19 business with three key
technical transfers, Avacta, Vatic and BioSure, all of which were
successfully transferred into manufacturing, which was a real
credit to the hard work and diligence of the Abingdon team, but
ultimately were not successfully commercialised by our customers
nor, therefore, for Abingdon . The anticipated manufacturing
volumes from these three products did not materialise and were a
key reason for the disappointing revenue performance in the
financial year. During the second half of 2022 we started to
rebuild our customer pipeline focusing on opportunities outside of
COVID-19 as we started to see, firstly, COVID-19 strategies across
many countries move towards treating it as a seasonal illness and
secondly many of our prospective customers move their product
development strategies away from COVID-19 and towards more
normalised activities.
Current Activity and Pipeline
We have seen an encouraging uplift in contract development
opportunities across a range of areas and we are expanding our
contract development team to support this increase in activity. We
believe our knowledge leadership position and our integrated
service offering is resonating with prospective customers who range
from small, innovative start-ups to some of the largest global
healthcare companies. We believe contract development will become a
significant driver of revenue growth in the short-term and beyond,
and will also drive increased opportunities for technical transfer
and manufacturing over time.
Technical transfer is the process of optimising and scaling up
the production processes of a developed assay for manufacture and
the production of three batches to allow validation and
verification of assay performance. We currently have two active
technical transfers that should be complete in H1 2023. We stopped
one transfer due to the instability of the product's manufacturing
process ( due to issues with the functioning of assay as provided
to us by our customer ) but we remain in contact with the customer
to see what additional support we can provide. We have a number of
additional transfer opportunities within our pipeline which we are
looking to bring in during the remainder of calendar year 2022 and
in 2023.
We have continued during 2022 to manufacture lateral flow tests
for customers across human health, animal health, plant health and
environmental testing. A key objective is to grow our manufacturing
base through successful transition of tests into manufacture and
importantly these will build "annuity income" to underpin future
revenues.
Team
During the financial year we reduced our average staff numbers
from 151 to 130, which sadly meant that a number of valued
colleagues were made redundant. The reason for the reduction was
the transition away from COVID-19 activity and the impact of the
delayed payment from DHSC. We continued to right-size the business
post FY22 year-end as manufacturing did not proceed from the three
COVID-19 projects as described above. This was despite successful
technical transfer of all three products. As at 31st October 2022
there were 71 employees within Abingdon.
We would like to thank all of the Abingdon team, both current
and past, for their hard work and support during an extremely
challenging period. The Board have been impressed by this
unwavering commitment to supporting our customers and providing a
first-class contract service despite the distractions.
Cost Restructuring
As noted above we right-sized the business during the financial
year and post year-end.
This involved a significant reduction in headcount as well as a
reduction in operational footprint and discretionary expenditure.
In 2020 and 2021 the Group had been built to service the
significant volume opportunities arising from COVID-19 testing.
However, these didn't materialise for various reasons and given the
uncertainty around the ongoing requirement for high volume COVID-19
testing it was necessary to reduce the cost-base of the business to
match more closely the commercial activity. The key focus of the
management team remains reducing the Group's cash burn and driving
the Company into positive cashflow. Based on the Group's forecasts
we believe that we have the financial resources in place to reach
this target.
As part of this restructuring we have limited our expenditure on
new product development. We have paused both the Flu and Hepatitis
C projects and have focused on completing the proof of concept of
the Lyme disease test. We remain enthusiastic about the commercial
opportunities for self-testing but are cognisant of the financial
investment needed in, for example clinical trials and regulatory
costs, to bring these products to market. Therefore, we believe it
is sensible to limit the expenditure in these areas for now and
focus the team's efforts of driving CDMO revenues with the aim of
positive cashflow .
Intellectual Property
The Company continues to protect its intellectual property
position and in the area of lateral flow device readers,
particularly the Company's AppDx(R) smartphone reader, has
continued to file UK and international patents. During the
financial year to June 2022 a patent was granted relating to
AppDx(R). Other patent applications continue including one relating
to a time-resolved fluorescence reader which has been given a
notice of grant for December 2022 and another ongoing application
relating to blood self-test apparatus.
Governance and People
Mary Tavener was appointed senior-independent non-executive
director in November 2020 prior to listing on AIM. Abingdon's other
non-executive director is Dr Chris Hand who is a co-founder of
Abingdon and non-executive chairman.
Lyn Rees (independent non-executive director) resigned as
non-executive director of the Company effective 30 September 2022
to focus on his responsibilities outside of the Company. We would
like to place on record our thanks and appreciation to Lyn for his
support and valued advice over the past three years.
Our Audit Committee and Remuneration Committee currently
comprises Mary Tavener (Chair) with Chris Hand (non-executive
chairman) and the executive directors Chris Yates and Melanie Ross
invited to attend as required from time-to-time. The Board has
concluded that at this time the Group does not currently require a
Nominations Committee but will review this assessment on a regular
basis including discussing the matter with its Nominated
Advisor.
Scott Page, Company Secretary and Finance Director, left
Abingdon Health in July 2022. The Board would like to place on
record their thanks to Scott for his hard work and contribution
over the past three years and wish him well for the future. Melanie
Ross, Chief Financial Officer, has taken over Company Secretary
responsibilities.
The Board remains focused on ensuring its own effectiveness and
that of the governance processes throughout the Group, and that
these governance structures remain fit for purpose as the Group
develops and grows over time. Mary Tavener is Abingdon's only
independent non-executive director and, as such, the Board's
current composition does not comply with the requirements for a
minimum of two independent non-executive directors under the QCA
Corporate Governance Code, being the corporate governance code that
the Company has chosen to apply. The Board believes, however, that
its current composition is appropriate for the current size of the
business and will continue to review its structure periodically as
the needs of the business change.
DHSC Dispute
We were pleased that in June 2022 we were able to reach a
settlement in relation to the dispute with the Department of Health
and Social Care ("DHSC"). The dispute resolution process arose due
to the lack of payment by DHSC for goods and services provided by
Abingdon.
It is disappointing that we, alongside many other UK diagnostic
companies, have had to spend time and money recovering monies owed
despite responding to a "call to arms" by the UK Government. The
Group believed at all times that there were no legal grounds as to
why these monies were not being paid in full by DHSC but the
reality was that it was important to reach a settlement with a
counter-party that effectively had unlimited time and financial
resources at its disposal to prolong the dispute. Given the UK
Government's initial aim at the start of the pandemic was to build
a British diagnostics industry their behaviours have been quite the
opposite, both in terms of how they have dealt with established UK
businesses and their preference to order significant quantities of
tests, through recently established intermediaries, predominantly
from Chinese companies.
The settlement agreement was in full and final settlement of the
outstanding debt of GBP8.9m (excluding interest) and comprised:
i ) A contractually required cash payment of GBP6.3m from DHSC
to Abingdon, which was paid as required to the Company on or before
22 July 2022;
ii) GBP1.5m of this cash payment was held under charge until the
outcome of a judicial review brought by the Good Law Project
Limited in challenge to the Secretary of State for Health and
Social Care, was known; this payment was subsequently released in
full to Abingdon;
iii) transfer to the Company of ownership of the outstanding
component stock that it had procured on behalf of DHSC in
2020/21;
iv) joint-ownership, alongside DHSC, of the intellectual
property of the AbC-19(TM) COVID-19 antibody test; and
v) a lower royalty payable to DHSC on sales of the AbC-19(TM)
COVID-19 antibody test, with this royalty time limited to one year
from the date of the settlement agreement.
The settlement of the DHSC dispute has led to an overall
exceptional write-off of GBP1.6m in the 2022 financial accounts.
This included legal costs of GBP0.2m in 2022 and GBP1.4m in total
in relation to writing off the outstanding balances relating to the
DHSC dispute. This is further broken down in note 5 below.
Judicial Review Process
In October 2022 Mr Justice Waksman issued his judgment in
relation to the Judicial Review proceedings initiated by the Good
Law Project Limited ("GLP") against the Secretary of State for
Health and Social Care in which Abingdon was an interested party.
Mr Justice Waksman ruled in favour of DHSC on all grounds,
including lack of state aid to Abingdon and dismissed all claims
brought by the GLP. GLP did not appeal the judgement.
Whilst we were pleased with the outcome, the impact that this
has had on Abingdon and its employees since late-2020 should not be
underestimated. Throughout the process the GLP made a number of
disparaging statements and unsubstantiated assertions about
Abingdon that have yet to be corrected, despite attempts being made
by Abingdon through its advisors inviting GLP to do so.
Abingdon fully supports both openness and accountability
relating to the award of public contracts; however, this particular
case brought by the GLP was comprehensively dismissed on all
grounds. Despite the Company's best efforts to cooperate and
demonstrate to the GLP that there was no bias or assistance in
these contracts being awarded, and to illustrate the impressive
credentials and experience of the Company and its employees in
lateral flow test development and manufacture, in the Board's
opinion, the proceedings continued long after they could have been
halted. This is particularly the case in view of the material facts
made available to GLP by Abingdon well over a year before judgment
with a view to informing the GLP of the factual background.
Abingdon incurred exceptional legal costs in 2022 of GBP0.2m,
and in total GBP0.3m in relation to the judicial review.
Outlook & Funding
Having raised GBP6.5m via a successful placing and
oversubscribed open offer in December 2021, the Company has no
current requirement for additional funding. Cash at the end of the
financial year was GBP2.4m and as of the end of October 2022 was
GBP4.4m. We believe we have sufficient cash resources to fund
progress beyond 12 months from the signing date of the accounts,
with our priority being to move the Company to a positive
cashflowposition.
Our strategic focus is on growing our CDMO business particularly
in non-COVID-19 markets in human health, animal health, plant
pathogen and environmental testing; particularly given the COVID-19
market outlook remains uncertain and volatile and appears to be
moving towards a seasonal infectious disease in a similar manner to
flu.
We are seeing our CDMO customer base expand and we are
encouraged by the growth in the range of potential opportunities.
Our key priorities are to grow our revenues and alongside this,
given the economically uncertain outlook, reduce our cash-burn
through continued close cost management. To this end we will focus
our team's activities on CDMO business and near-term revenues with
own-product development being given less priority until we are
closer to break-even.
The lateral flow testing market is forecast to strongly grow for
the next decade and Abingdon as a knowledge leader in the sector
with a well-established track record of bringing products from
"idea to market" is well-placed to support a broad range of
customers. We believe our full-service contract service proposition
strongly resonates with customers and we look forward to building
our business after an extremely challenging two years during where
COVID-19 dominated our industry.
We would like to thank all our employees for their hard work,
dedication and commitment during the past year despite the
challenges we have faced in an uncertain economic climate. We are
confident with our contract services customer base and our current
growing pipeline means we are well positioned to grow our business
and deliver shareholder value going forward. We would like to thank
shareholders for their support.
Stakeholder Engagement
The Board of Directors of the Abingdon group of companies (the
"Group") considers that, individually and collectively, it has
acted in the way which in good faith would be most likely to
promote the success of the Group for the benefit of its
stakeholders, employees, customers, suppliers, local government and
communities in accordance with the stakeholder and matters noted in
S172(1)(a-f) of the Act in the decisions taken during the year
reported on, having regard to:
-- The likely consequences of any decision in the long term;
-- The interests of the Group's employees;
-- The need to foster the Group's business relationships with
suppliers, customers and others;
-- The need to regularly communicate with our shareholders;
-- The impact of the Group's operations on the community and the
environment;
-- The desirability of the Group in maintaining a reputation for
high standards of business conduct; and
-- The need to act fairly between members of the Group.
The Board looked to promote the success of the Group, having
regard to the long term, whilst considering the interests of all
stakeholders. Our strategy is designed to secure the long-term
financial viability of the Group to the benefit of its members and
all stakeholders. A main feature of this is to continue to operate
the business within tight budgetary controls and in line with
regulatory requirements. During the year this was done by reference
to:
-- our continued and ongoing communication with our
employees;
-- our continued and ongoing communication with our
shareholders;
-- our continued priority for health and safety improvement
measured through ongoing risk assessments;
-- the approval of our strategic objectives ('our strategy') for
the Group; and
-- the business plan for the next financial year ('our
plan').
Stakeholder interests are considered by the Board through a
combination of methods.
Shareholders
We communicate with our shareholders through planned investor
relation activities, Regulatory News Service ("RNS") announcements
and the publication of our annual and half year reports. Through
this we ensure our shareholders are provided with insight into the
Group strategy and how we create value that will generate strong
and sustainable results. We also engage with shareholders through
the AGM, one on one investor meetings and discussions with
shareholders where appropriate. The Board were mindful to inform
shareholders of the progress of both the DHSC dispute and the GLP
legal case throughout.
Customers
Our customers are central to the strategic goals of the Group,
and we strive to deliver products that meet not only their specific
needs, but the highest applicable regulatory standards. We engage
regularly with our customer base and conduct annual customer
experience surveys, taking action where appropriate. We also meet
our customers' needs by maintaining facilities that are compliant
to appropriate quality and regulatory standards and have dual site
capability as part of our disaster recovery planning.
Employees
We appreciate the value of diversity within our employee base
and recognise that the skills and knowledge of our employees is a
key part of creating value within the organisation. We strive to
create a friendly and open culture within the Group, holding
regular all-staff calls led by either the CEO, CFO or COO and
encourage career progression within the Group.
The Group conducts an annual employee feedback survey, the
results of which are reported to the Board and fed back to the
employees along with any resulting actions. The Group has also
encouraged the creation of an Employee Forum to more directly
communicate both employee thoughts, considerations and needs to the
senior management.
Open door sessions have also been conducted during the year to
ensure open communication regarding matters such as health and
safety and COVID-19 concerns.
The business had hopes that the changes made to the people
infrastructure during the last fiscal year would see an end to the
reduction in our headcount, but unfortunately we reluctantly
entered into additional redundancy consultations with employees in
roles that were identified 'at risk' during the 2021/22 fiscal
year. This process has enabled the business to right size itself
for the short- and medium-term opportunities that it predicts most
likely to occur, whilst remaining nimble enough to respond to
changes in forecasts going forwards. At every stage of the process
employees were kept informed and provided with appropriate
support.
Dr Chris Hand Chris Yates
Non-Executive Chairman Chief Executive Officer
24 November 2022
Operating and Financial Review
Revenue and Margins
In the year revenue fell 76% to GBP2.8m (2021: GBP11.6m).
Excluding DHSC revenue from the prior year, revenue fell 56%.
Revenue by Geographical Market
Geographical 2022 2021 Growth/
Market GBPm % GBPm % (Decrease)
----------------- -------- ------ ------- ------ -------------
UK 1.4 50% 6.6 57% (79)%
USA/Canada 0.2 6% 3.4 29% (95)%
Europe 1.0 38% 1.5 13% (31)%
ROW 0.2 6% 0.1 0% 185%
Total 2.8 100% 11.6 100% (76)%
------------------ ------- ------ ------- ------ -------------
Revenue by Operating Segment
2022 2021 Growth/
Operating Segment GBPm % GBPm % (Decrease)
------------------------- ------- ------ ------- ------ -------------
Products 0.4 16% 8.3 72% (95)%
Contract Manufacturing 1.1 40% 1.7 15% (37)%
Contract Development 1.3 44% 1.6 13% (14)%
Total 2.8 100% 11.6 100% (76)%
------------------------- ------- ------ ------- ------ -------------
Contract Manufacturing (manufacture of products to a defined
specification leading to recurring revenues, secured by customer
contracts) fell 34% over the period, predominantly due to two
customer products and their customer-supplied components requiring
additional design activity, leading to a GBP0.4m year on year
reduction in sales. Both products are scheduled to return to
production in H2 22/23.
Product sales (own products that are part of our product
catalogue that can be ordered via the website or through a network
of distributors) reduced to GBP0.4m in the relevant period. 21/22
sales include DHSC revenue of GBP5.2m and GBP2.8m of sales to a
customer in the USA of our PCRD product for incorporation into
their own device. Excluding these non- repeating customers, like
for like sales fell 7%.
Contract Development (R&D activity based on a day rate,
developing and scaling up customer products as a fee for service)
decreased 21%, It is important to note that whilst revenue for
scale up to manufacture would typically be expected to lead to
meaningful Contract Manufacturing revenue, three customers in this
area subsequently failed to move into manufacture for
customer-related reasons.
Gross margin in the financial year was (116)%, though this
includes provisions for stock write off of GBP3.7m, mainly relating
to Abingdon owned AbC-19 stock and an increase in provisions for
obsolete items. Adjusting for this one-off charge, underlying gross
margin was 3%. This direct gross profit margin continued to be
impacted by the reduced level of manufacturing output in relation
to the labour overhead, carried due the expectation that contracts
would transition into contract manufacturing in the early new year.
As previously explained, this did not happen and this overhead has
since been reduced.
Adjusted EBITDA
The Group uses adjusted EBITDA as this excludes items which can
distort comparability as well as being the measure of profit that
most accurately reflects the cash generating activities of the
Group. The reconciliation of these adjustments is as follows:
Year Ended Year Ended
30 June 2022 30 June 2021
GBP'000 GBP'000
Adjusted EBITDA (9,997) (3,256)
Share based payment expense (231) (1,367)
Impairment charges (7,192)
Non-recurring legal and professional
fees (688) (257)
Non-recurring employee costs (198) (188)
Listing costs (903)
DHSC related costs (1,585)
Net Finance costs (65) (234)
--------------- ---------------
Statutory EBITDA (19,956) (6,205)
--------------- ---------------
Amortisation (121) (42)
Depreciation (1,516) (707)
--------------- ---------------
Operating Loss (21,593) (6,954)
--------------- ---------------
Adjusted EBITDA loss in the period was GBP10.0m (2021: loss
GBP3.3m).
Headcount in the Group was an average of 130 (2021: 151) peaking
at 133 in the reporting period. Consequently, staff costs overall
reduced to GBP5.3m (2021: GBP7.4m) reflecting the full year impact
of the reduction in heads implemented during the previous year, and
the savings associated with the second redundancy programme in the
current fiscal year. Exceptional costs of GBP0.2m were incurred in
the year due to this redundancy programme.
Professional costs in the year were GBP1.5m (2021: GBP1.9m).
This falls to GBP0.6m when excluding non-recurring costs associated
with the fund raise, completed in December 2021, legal costs
associated with the DHSC and the GLP challenge and costs incurred
in pursuing acquisition opportunities, subsequently aborted. Legal
costs within the financial year relating to the contractual dispute
with the DHSC totalled GBP0.2m, and the costs associated with the
GLP legal case were GBP0.3m.
Obsolescence provisions totalling GBP3.7m have been made in the
period. These predominantly fall into two categories, being those
non AbC-19(TM) raw materials (GBP1.0m) that fall into ageing
categories under which we automatically provide against and certain
finished goods and semi-finished goods relating to AbC-19(TM)
(GBP2.7m) which are flagged as obsolete as we continue to review
this product's place in the current market. Stock holding continues
to be an area of focus to both support customer requirements and
control working capital. Separate provisions have been made in
exceptional costs for the DHSC owned stock which transferred to
Abingdon as part of the settlement agreement (see Note 5).
Impairment of Assets
The Directors have compared the projected results of the Group
to the carrying value of its property, plant and equipment, which
is considered to form a single cash generating unit ("CGU") for
impairment testing purposes. The Group had invested heavily in
growing the capacity of the Group in anticipation of the DHSC
contract fulfilment, along with associated contracts.
The future cashflows were tested on a group basis, which showed
an estimated present value of future cashflows into perpetuity of
GBP1.8m, representing an overall impairment of GBP7.2m. This was
discounted at a rate of 23.7% and with a long-term growth
normalising at 3.0%. The Directors also performed a complementary
check of the expected capacity modelling for each key machine,
which approximated to the outcome of the cashflow model.
The impairment has been charged first to goodwill to eliminate
this, with the remainder of the charge allocated first to reduce
the value of right of use assets and leasehold improvements to a
fixed level, and then pro-rated across all other assets, excluding
new intangible assets in two subsidiaries.
Cash Resources
Net cash outflow from operating activities was GBP7.7m (2021:
outflow GBP12.9m). A reduction year-on-year in payables and the
unwinding of the DHSC contract stock and payable amounts following
the conclusion of the dispute being the main drivers.
The net proceeds from financing activities were from the
completion of the fundraise in December 2021 when the Group raised
money through a placing. Altogether this represented a net cash
decrease of GBP2.6m when compared to the prior year, with a closing
cash position of GBP2.4m (2021: GBP5.0m).
Financing
Post-year-end, the dispute with the DHSC was concluded and in
July 2022 the business received GBP6.3m cash in full settlement of
the disputed amounts. Cash at the end of October was GBP4.4m .
Earnings per Share
Earnings per share was a loss of 7.29p in the period and
adjusted EPS was a loss of 3.43p in the same period.
EPS
Basic EPS (7.29)p
Loss attributable to Shareholders GBP(21.6)m
Add: Share Based Payments GBP0.2m
Add: Non recurring legal fees GBP0.7m
Add: Non recurring employment costs GBP0.2m
Add: impairment charge GBP7.2m
Add: Other Costs relating
to DHSC Settlement GBP1.6m
Add: Depreciation and Amortisation GBP1.6m
Add: Finance Costs GBP0.1m
Adjusted Loss attributable to Shareholders GBP(10.0)m
Adjusted EPS (3.43)p
---------------------------------------------- ------------
Principal Risks and Uncertainties
Indication
Risk of risk on Impact and description Mitigating actions
prior year
Funding risk Risk decrease The cash position as GBP6.3m was received from
and material vs prior year at 31 October 2022 is the DHSC, with GBP1.5m of
uncertainty GBP4.4m this put in a blocked account
in relation pending the result of the
to Going Concern Good Law Project court case.
This has now concluded and
the funds have been released.
The Business continues to
grow its revenue generating
opportunities and has a
strategy in place to develop
long term relationships
from Contract Development
through to Contract Manufacturing.
Costs are also regularly
reviewed to ensure that
they are line with the needs
of the business and continue
to give the business sufficient
runway.
------------------- ----------------------------- --------------------------------------
Infectious Risk remains A future escalation Dual site manufacturing
Diseases the same vs in the spread of COVID-19 capability across the primary
and prior year or another pandemic manufacturing process in
business type disease in the both York and Doncaster.
interruption UK poses a threat to
the continuation of Cross functional teams and
business operations shift rotations creating
if there is a widespread bubble environments to mitigate
infection in any of the risk of people being
our facilities or amongst unable to complete activities
the workforce. in either R&D or Operations.
Supply chain activities
This would also apply are focused on managing
to risk in the Customer both our relationships with
and Supplier profiles suppliers, as well as these
where crucial components risks through supply chain
and raw materials become diversification and dual
scarce and difficult sourcing considerations.
to import.
------------------- ----------------------------- --------------------------------------
Indication
Risk of risk on Impact and description Mitigating actions
prior year
Regulatory Risk remains As a business that supplies We have a team of Quality
Approval same vs prior to international Customers and Regulatory specialists
year a significant proportion in house who can work on
of the products where multiple registrations in
we are acting as Legal parallel to increase the
Manufacturer require likelihood of approvals.
registration from multiple
regulatory bodies prior Our EU representative for
to being offered for our products, Advena, have
sale. offices in Malta and the
UK and advise on EU specific
There is no guarantee matters and IVDR.
that any product registration
by the Group will be
successful and failure
to do so could have
a major impact upon
the Group's ability
to sell products in
the relevant country.
------------------- --------------------------------- -------------------------------------
Revenue Risk remains If Revenue Growth is Strategic plan to bring
Growth the same vs not continuously achieved more Research and Technical
prior year there is a risk that Transfer stage projects
capacity will be under through the R&D Team. This
utilised. generates revenue in the
short term and will lead
to longer term sustainable
relationships with customers.
The number and quality of
customers in this area is
high, giving the Board sufficient
confidence in achieving
sales growth.
Use of automated lateral
flow assembly equipment
with versatile equipment
which can changeover product
types and increase the throughput
in Operations.
------------------- --------------------------------- -------------------------------------
Indication
Risk of risk on Impact and description Mitigating actions
prior year
Key Employees Risk remains The Group operates in The Group offers competitive
same vs prior an industry where recruitment salary and benefits packages
year and retention of talented to employees.
employees is crucial
in being able to deliver Our personal development
the strategic objectives. review process aids in both
identifying areas of focus
Talent pools in the and success, as well as
industry are not as identifying talented individuals
immediately available and the program of training
as they may have been that is needed to help them
12-24 months ago so and the business achieve
the Group must be proactive its highest potential
in talent attraction.
Recent redundancies
have meant that the
Group have had to work
harder to retain and
attract in an already
difficult market.
----------------- --------------------------------- --------------------------------------
Supply Chain Risk remains The supply chain is Contractual arrangements
same vs prior subject to price movements in place offer some mitigation
year due to inflationary for component pricing.
pressure as well as
other potential factors Suppliers are measured with
such as COVID related robust key performance indicators,
transport cost increases. with our highest-level suppliers
being audited by our quality
This may lead to increasing assurance team annually.
prices for goods as Supply of stock to achieve
well as increased lead on time delivery to customers
times for critical components is managed robustly to ensure
that we meet our customers'
needs without holding unrequired
amounts of stock.
Where managing supply chain
activities for new products
and customers, the team
recognise that there is
a balance between the pricing
of components and their
availability due to location
of manufacture. This is
managed accordingly with
appropriate stockholding
or dual sourcing where possible.
----------------- --------------------------------- --------------------------------------
Going concern
The Directors have prepared cash flows for the foreseeable
future, being a period of at least 12 months from the expected date
of approval of the financial statements and continue to evaluate
financial forecasts. The Group continues to focus on securing sales
of existing and new products, partnering with other Companies to
develop products for manufacture and transition these in a timely
manner. At 30 June 2022 the bank balance was GBP2.4m. Post year
end, GBP6.3m was received from the DHSC in full settlement of the
outstanding monies owed from the three contracts in dispute. Cash
at the end of October was GBP4.4m. This draws to a conclusion all
the contractual commitments in those relationships.
The Board is satisfied that based on current forecasts, there is
sufficient headroom and concluded that it is appropriate to prepare
the Annual Report and Accounts on a going concern basis.
Events after the reporting date
Following the signing of the settlement agreement on the 22nd
June, the monies agree, being GBP6.3m, were paid in full with
GBP1.5m being put aside in a blocked account pending the conclusion
of the judicial review. This money has now been released in full to
Abingdon.
Consolidated Statement of Comprehensive Income
For the Year Ended 30 June 2022
Year ended Year ended
30 June 30 June
Notes 2022 2021
GBP'000 GBP'000
Revenue 1 2,835 11,618
Cost of sales (6,427) (7,475)
------------ ------------
Gross (loss)/profit (3,592) 4,143
Administrative expenses (6,645) (7,547)
Other income 240 148
Adjusted EBITDA (before adjusting items) (9,997) (3,256)
Amortisation (121) (42)
Depreciation (1,516) (707)
Impairment charges (7,192) -
Share based payment expense (231) (1,367)
Non-recurring legal, professional and
fundraising fees (688) (257)
Listing costs - (903)
Non-recurring redundancy costs (198) (188)
Other exceptional costs relating to
DHSC settlement 5 (1,585) -
-------------------------------------------- --------- ------------ ------------
Operating loss (21,528) (6,720)
Finance income 4 -
Finance costs (69) (234)
------------ ------------
Loss before taxation (21,593) (6,954)
Taxation credit/(charge) 2 331 (19)
Loss for the financial period (21,262) (6,973)
------------ ------------
Other comprehensive income for the year
net of tax - -
------------ ------------
Total comprehensive loss for the year (21,262) (6,973)
------------ ------------
Attributable to:
Equity holders of the parent (21,262) (6,973)
------------ ------------
Basic earnings per share (pence) 4 (7.29) (2.65)
-------- --------
Diluted earnings per share (pence) 4 (7.29) (2.65)
-------- --------
Consolidated Statement of Financial Position
As at 30 June 2022
Notes 30 June 30 June
2022 2021
GBP'000 GBP'000
Non-current assets
Goodwill - 763
Other intangible assets 36 465
Property, plant, and equipment 1,777 9,041
1,813 10,269
Current assets
Inventories 534 7,888
Trade and other receivables 7,844 9,978
Income tax receivable 183 115
Cash and cash equivalents 2,397 4,977
---------- ---------
10,958 22,958
---------- ---------
Total assets 12,771 33,227
---------- ---------
Current liabilities
Trade and other payables 5,059 10,405
Borrowings 115 125
Obligations under leases 150 227
5,324 10,757
Non-current liabilities
Borrowings 435 367
Obligations under leases 580 776
1,015 1,143
Total liabilities 6,339 11,900
Net assets 6,432 21,327
---------- ---------
Equity
Attributable to the owners of the parent:
Share capital 6 76 69
Share premium 30,309 24,180
Share based payment reserve 6 153 44
Retained losses (24,106) (2,966)
---------- ---------
Total equity 6,432 21,327
---------- ---------
Consolidated Statement of Changes in Equity
For the Year Ended 30 June 2022
Share Share premium Share Retained Total equity
Capital based earnings attributable
payment to owners
reserve of the parent
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Balance at 1 July 2020 15 13,195 70 (10,531) 2,749
Year ended 30 June 2021:
Profit and loss - - - (6,973) (6,973)
---------- --------------- ---------- ----------- ----------------
Total comprehensive loss
for the year - - - (6,973) (6,973)
Other movements:
Capital reduction - (13,145) - 13,145 -
Bonus share allotment 46 (46) - - -
Share option expenses - - 1,367 - 1,367
Share options vested 1 - (973) 973 1
Share options cancelled - - (420) 420 -
Conversion of loan notes 1 3,481 - - 3,482
Shares issued on listing 6 21,994 - - 22,000
Cost of issue of shares - (1,299) - - (1,299)
Balance at 30 June 2021 69 24,180 44 (2,966) 21,327
---------- --------------- ---------- ----------- ----------------
Year ended 30 June 2022:
Profit and loss - - - (21,262) (21,262)
---------- --------------- ---------- ----------- ----------------
Total comprehensive loss
for the year - - - (21,262) (21,262)
Other movements:
Share option expense - - 231 - 231
Share options exercised - - (10) 10 -
Share options cancelled - - (112) 112 -
Issue of shares 7 6,493 - - 6,500
Cost of issue of shares - (364) - - (364)
Balance at 30 June 2022 76 30,309 153 (24,106) 6,432
---------- --------------- ---------- ----------- ----------------
Consolidated Statement of Cash Flows
For the Year Ended 30 June 2022
30 June 30 June
2022 2021
GBP'000 GBP'000
Cash flows from operating activities:
Loss for the year (21,262) (6,973)
Adjustments for:
Other income (240) (148)
Net finance costs 65 234
Tax (credit)/charge (331) 19
Amortisation and impairment of intangible
assets 1,270 42
Share based payments 231 1,367
Depreciation and impairment of property,
plant and equipment 7,559 707
Loss on disposal of property, plant 240 -
and equipment
Impairment of Inventories (including 9676 -
DHSC)
Changes in working capital:
Decrease/(increase) in inventories 2.322 (7,109)
Decrease/(increase) in trade and
other receivables 2,134 (8,103)
(Decrease)/increase in trade and
other payables (5,170) 7,033
Cash used in operations (8,150) (12,931)
Interest paid (including leases) (58) (51)
Income taxes received 323 106
Insurance claim proceeds 146 -
Net cash outflow from operating
activities (7,739) (12,876)
Interest received 4 -
Purchase of intangible assets (78) (71)
Internally capitalised development
costs - (419)
Purchase of property, plant and equipment (682) (6,761)
Proceeds on disposal of property,
plant and equipment - 8
Payment of deferred consideration - (32)
Net cash used in investing activities (756) (7,275)
---------- ----------
Consolidated Statement of Cash Flows
For the Year Ended 30 June 2022 (continued)
30 June 30 June
2022 2021
GBP'000 GBP'000
Financing activities
Proceeds from issue of own shares
(net of costs *) 6,136 20,702
Cash withheld for SAYE scheme (7) 9
Proceeds from new bank loans and
borrowings 167 250
Payment of loans (125) (19)
Payment of lease obligations (144) (222)
Payment on settlement of accrued (112) -
lease obligations
Proceeds from issue of loan notes - 20
--------- ---------
Net cash generated from financing 5,915 20,740
--------- ---------
Net (decrease)/increase in cash
and cash equivalents (2,580) 589
Cash and cash equivalents at beginning
of the year 4,977 4,388
--------- ---------
Cash and cash equivalents at end
of the year 2,397 4,977
========= =========
Recognised in the Statement of Financial
Position as:
Cash at bank and in hand 2,397 4,977
Overdrafts - -
--------- ---------
2,397 4,977
--------- ---------
* Net of costs of GBP364,000 (2021 - GBP1,298,000) set against
the share premium account only. In the prior year additional costs
of admission to AIM are included within exceptional costs in the
Statement of Comprehensive Income and are shown as Operating
cashflows.
Abingdon Health PLC
Notes to the Financial Statements
For the Year Ended 30 June 2022
Company information
Abingdon Health PLC ("the Company") is a public limited company
domiciled and incorporated in England and Wales. The Company is
quoted on the London Stock Exchange's Alternative Investment Market
("AIM"). The registered office is York Biotech Campus, Sand Hutton,
York, YO41 1LZ. The consolidated financial information (or
"financial statements") incorporates the financial information of
the Company and entities (its subsidiaries) controlled by the
Company (collectively comprising the "Group").
The principal activity of the Group is to develop, manufacture
and distribute diagnostic devices and provide consultancy services
to businesses in the diagnostics sector.
Basis of preparation
The financial information set out in this preliminary
announcement does not constitute statutory accounts as defined by
section 434 of the Companies Act 2006.
The financial information for the year ended 30 June 2022 and
the year ended 30 June 2021 does not constitute the Company's
statutory accounts for those years. Statutory accounts for the year
ended 30 June 2021 have been delivered to the Registrar of
Companies. The statutory accounts for the year ended 30 June 2022
were approved by the Board on 23 November 2022 and will be
delivered to the Registrar of Companies in due course. The
statutory accounts for the period ended 30 June 2022 will be posted
to shareholders at least 21 days before the Annual General Meeting
and made available on the Group's website .
The Group's statutory financial statements for the year ended 30
June 2022, from which the financial information presented in this
announcement has been extracted, were prepared in accordance with
international accounting standards in conformity with the
requirements of the Companies Act 2006. The financial statements
have been prepared on the historical cost basis with the exception
of certain items which are measured at fair value as disclosed in
the principal accounting policies set out in the Group's Annual
Report. These policies have been consistently applied to all years
presented.
The preparation of financial statements in conformity with IFRS
requires the use of estimates and assumptions that affect the
reported amounts of assets and liabilities at the date of the
financial statements and the reported amounts of revenues and
expenses during the reporting period. Although these estimates are
based on management's best knowledge of the amount, event or
actions, actual results ultimately may differ from these
estimates.
The auditor's reports on the accounts for 30 June 2022 and 30
June 2021 were unqualified and did not contain a statement under
498(2) or 498(3) of the Companies Act 2006. The auditor's report
for the year ended 30 June 2021 did include a reference to a
material uncertainty related to going concern, drawing attention to
the fact that the Company was dependent on the recoverability of
amounts owed by the Department of Health and Social Care which was
being pursued through a dispute resolution process in the Contract,
or was required to investigate further funding and reduce costs
further in the near term, without qualifying their report. The
opinion was not modified in respect of this matter. The auditor's
report for the year ended 30 June 2020 did not draw attention to
any matters by way of emphasis.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements in conformity with
IFRS requires management to make judgments, estimates and
assumptions that affect the application of policies and reported
amounts of assets and liabilities, income and expenses. The
estimates and associated assumptions are based on historical
experience and various other factors that are believed to be
reasonable under the circumstances, the results of which form the
basis of making the judgements about carrying values of assets and
liabilities that are not readily apparent from other sources.
Actual results may differ from these estimates.
Estimates and underlying assumptions are reviewed on an ongoing
basis. Revisions to accounting estimates are recognised in the
period in which the estimate is revised and in any future periods
affected.
Critical judgements
The following judgements (apart from those involving estimates)
have had the most significant effect on amounts recognised in the
financial statements:
Right of use asset recognition
Management have assessed each lease liability for recognition
under IFRS 16 and recognised a right of use asset where
appropriate.
One lease includes a material component of service charge by
comparison to the headline rental payments, where this service
charge partially covers shared areas and facilities which would
normally form part of a rental price. The Directors have applied
judgement in splitting this service charge into rent-like
components of GBP24,000 per annum (which qualify for capitalisation
as a right of use asset), utility fees of GBP104,000 per annum, and
ongoing shared costs of GBP72,000 per annum (which the latter two
do not qualify for capitalisation as a right of use asset, nor
recognition as a lease liability). The lease runs for a 7-year term
and the total value of rent-like components capitalised (prior to
amortisation) is GBP161,000.
Revenue recognition
In line with IFRS 15 management are required to determine
appropriate revenue recognition points for all revenue streams.
Where multiple contracts are entered into with a single
counterparty any instalment payments are not considered to be a key
indicator of the satisfaction of a performance obligation, although
linked contracts with a counterparty are considered in conjunction
when identifying the appropriate point for revenue recognition.
Key sources of estimation uncertainty
The estimates and assumptions which have a significant risk of
causing a material adjustment to the carrying amount of assets and
liabilities are as follows:
Valuation of intangible assets (Group 2022: GBP36,000; 2021:
GBP465,000)
Management judgements are required to estimate the useful lives
of intangible assets, having reference to future economic benefits
expected to be derived from use of the asset. Economic benefits are
based on the fair values of estimated future cash flows.
Management further test the assets for impairment on an annual
basis, by reference to future plans and expectations for group
revenues and profits. An impairment of GBP386,000 has been
recognised against intangible assets during the year
Valuation and impairment of cash generating units (including
goodwill)
Goodwill is tested annually for impairment as part of a cash
generating unit ("CGU"). The test considers future cash flow
projections of each CGU on a group basis, as the group as a whole
is considered to be a single CGU. In the current year, two tests
have been performed, a discounted cash flow model and a
value-in-use model, which have both approximated to the same
value.
Where the discounted cash flows are less than the carrying value
of the CGU, an impairment charge is recognised for the
difference.
Share based payments
The determination of the fair values of EMI and SAYE options has
been made by reference to the Black-Scholes model.
Going concern
In their assessment of the Group's ability to continue as a
going concern, the Directors have considered the principal risks
and uncertainties facing the business, along with the Group's
objectives, policies and processes for managing its exposure to
financial risk. In making this assessment the Directors have
prepared cash flows for the foreseeable future, being a period
through to 30 June 2024, and continue to evaluate financial
forecasts for revenue, expenditure and cash flows.
Net cash at the end of the year was GBP2.4m, and the group
received GBP6.3m in full and final settlement of the DHSC
outstanding amounts in July (post year-end). Cash at the end of
October was GBP4.4m.
As set out above, the business continues to focus on securing
sales of existing and new products, and in particular are seeing an
uplift in the amount of CDMO customers we are in meaningful
discussions with, which should lead to repeatable revenue, driving
top line growth in the Group.
Having considered all the above, the Directors have prepared the
financial statements on a going concern basis.
Non-recurring income and costs
The Group seeks to highlight certain items as exceptional
operating income or costs. These are considered to be exceptional
in size, frequency and/or nature rather than indicative of the
underlying day to day trading of the Group. These may include items
such as acquisition costs, restructuring costs, obsolescence costs,
employee exit and transition costs, legal costs, profits or losses
on the disposal of subsidiaries, and loan impairments. All of these
items are charged or credited before calculating operating profit
or loss.
The Directors apply judgement in assessing the particular items,
which by virtue of their size and nature are disclosed separately
in the Statement of Comprehensive Income and the notes to the
financial statements as non-recurring income and costs. The
Directors believe that the separate disclosure of these items is
relevant to understanding the Group's financial performance.
Guarantees, commitments and contingent liabilities
At 30 June 2022, the Group and Company had no contingent
liabilities (2021 - none).
At 30 June 2022 the Group had contracted for capital commitments
of approximately GBPnil (2021 - GBP0.8 million). These amounts have
not been reflected in the financial statements.
1. Revenue
The Group applies IFRS 15 'Revenue from contracts with
customers'. Under IFRS 15, the Group applies the 5-step method to
identify contracts with its customers, determine performance
obligations arising under those contracts, set an expected
transaction price, allocate that price to the performance
obligations, and then recognises revenues as and when those
obligations are satisfied.
Segmental analysis of revenue
2022 2021
GBP'000 GBP'000
Product sales 465 8,360
Contract Manufacturing 1,124 1,690
Contract Development 1,246 1,568
Total revenue from contracts with customers 2,835 11,618
--------- ---------
Revenue analysed by geographical market
2022 2021
GBP'000 GBP'000
United Kingdom 1,417 6,596
Europe 1,072 1,560
USA & Canada 182 3,405
Rest of World 164 57
--------- ---------
2,835 11,618
--------- ---------
All revenue received in the current and comparative years has
been recognised at a point in time in accordance with the Group's
revenue recognition policy.
2. Taxation
The tax expense represents the sum of the tax currently payable
and deferred tax.
2022 2021
GBP'000 GBP'000
Current tax
UK Corporation tax on profits for the
current year - 19
Adjustments in respect of prior years (331) -
Total current tax (331) 19
Deferred tax
Origination and reversal of temporary - -
differences
--------- ---------
Impact of change in tax rates - -
--------- ---------
Total deferred tax - -
--------- ---------
Total tax (credit)/charge (331) 19
--------- ---------
The charge for the year can be reconciled to the profit per the
Consolidated Statement of Comprehensive Income as follows:
2022 2021
GBP'000 GBP'000
(Loss) before taxation (21,593) (6,954)
---------- ---------
Expected tax (credit) based on a corporation
tax rate of 19% (2021 - 19%)
(2019 - 19%) (4,103) (1,321)
Tax effect of expenses that are not deductible
in determining taxable profit 717 228
Depreciation on assets not qualifying for
tax allowances 316 94
Change in unrecognised deferred tax asset 3,072 1,629
Share based payments 44 (705)
Prior Year Adjustment (331) -
Other differences (46) 94
Total tax (credit)/charge (331) 19
---------- ---------
The UK corporation tax rate was 19% throughout the year.
On 3 March 2021, the Chancellor of the Exchequer announced that
the main rate of corporation tax in the United Kingdom will rise to
25% with effect from 1 April 2023 for companies earning annual
taxable profits in excess of GBP250,000. Deferred tax balances at
the reporting date are therefore measured at 25% (2021: 25%; 2020:
19%).
3. Dividends
No dividends were paid in the current or prior year.
4. Earnings per share
The calculation of the basic and diluted earnings per share is
based on the following data:
2022 2021
Earnings used in calculation (GBP'000) (21,262) (6,973)
Weighted average number of ordinary
shares 291,622,638 262,926,110
Basic EPS (pence/share) (7.29) (2.65)
Weighted average number of dilutable
shares 291,622,638 262,926,110
Diluted EPS (pence/share) (7.29) (2.65)
The diluted EPS is the same as the Basic EPS as there is a loss
for each of the periods concerned.
In each period there were share options outstanding. As at 30
June 2022, options which are out of the money are excluded from the
calculation of the weighted average number of dilutable shares.
The Directors use adjusted earnings before certain non-recurring
costs ("Adjusted Earnings") as a measure of ongoing performance and
profitability. These non-recurring costs are presented as separate
items on the face of the Consolidated Income Statement.
The calculated Adjusted Earnings for the current and comparative
periods are as follows:
2022 2021
GBP'000 GBP'000
Loss before taxation attributable to
equity owners of the Parent (21,593) (6,954)
Share-based payment costs 231 1,367
Impairment charges 7,192 -
Non-recurring legal fees 688 257
Listing costs - 903
Non-recurring employee redundancy costs 198 188
Exceptional costs relating to settlement 1,585 -
of DHSC contract (see note 5)
Depreciation and amortisation 1,638 749
Finance costs 69 234
Adjusted Earnings (9,992) (3,256)
---------- ---------
Basic and diluted Adjusted Earnings
per share (pence/share) (3.43) (1.25)
The calculation of Adjusted Earnings is consistent with the
presentation of Adjusted Earnings before Interest, Tax,
Depreciation, and Amortisation, as presented on the face of the
Statement of Comprehensive Income. This adjusted element also
removes non-recurring items, as explained further above. The
Directors have presented this Alternative Performance Measure
("APM") because they feel it most suitably represents the
underlying performance and cash generation of the business, and
allows comparability between the current and comparative period in
light of the rapid changes in the business (most notably its
admission to AIM and associated costs), and will allow an ongoing
trend analysis of this performance based on current plans for the
business.
5. Impact of Department of Health and Social Care ("DHSC")
Contract on the Income Statement (IS) and the Statement of
Financial Position ("SFP")
Following the long-standing dispute between the Company and
DHSC, which was disclosed in note 16 to the prior year's financial
statements, the Company and DHSC signed a settlement agreement in
June 2022. This resulted in the full and final payment of monies
owed to the Company on 7 July 2022.
However, the settlement included a number of adjustments to the
outstanding monies owed to the Company. All such adjustments have
been recognised within the current year's financial statements as
follows:
Description of adjustment Location in financial IS Amount GBP'000
statements
Exceptional costs
Acquisition and impairment of inventories - DHSC (5,536)
Relinquishing of payable to DHSC Exceptional costs
for components - DHSC 4,579
Credit loss arising on the outstanding Exceptional costs
receivable from DHSC - DHSC (600)
Cancellation of accrued royalty Exceptional costs
payments - DHSC 6
Exceptional costs
Interest received on overdue payment - DHSC 168
Exceptional costs
Other legal fees (see below) - DHSC (202)
--------------------------------------
Net (expense) to IS (1,585)
--------------------------------------
Other legal fees include significant legal costs in defending
the Company's position totalling GBP202,000, which have also been
recognised within exceptional costs relating to the DHSC
contract.
Following the adjustments described above, the Company has the
following inclusions on its SFP as at the year end in relation to
DHSC:
2022 2021
Group GBP'000 GBP'000
Inventories - 3,987
Trade receivables (inclusive of VAT but after
irrecoverable amounts) 6,266 6,410
Contract liability - (5,308)
Net impact on SFP 6,266 5,089
--------- ---------
The total net exposure was received in cash on 7 July 2022. The
Company does not believe it has any further exposure to future
costs or risks associated with this contract.
6. Share capital and reserves
2022 2021
Ordinary share capital
Authorised Number Number
Ordinary shares of 0.025p each 121,711,614 95,699,114
Deferred shares of 0.025p each 182,316,812 182,316,812
------------- -------------
304,028,426 278,015,926
------------- -------------
Allotted and fully paid Number Number
Ordinary shares of 0.025p each 121,711,614 95,699,114
Deferred shares of 0.025p each 182,316,812 182,316,812
------------- -------------
304,028,426 278,015,926
GBP'000 GBP'000
Ordinary shares of 0.025p each 31 24
Deferred shares of 0.025p each 45 45
76 69
------------- -------------
On 21 December 2021 the Company raised GBP6.5 million (before
expenses) by way of issuing 26,000,000 ordinary shares of 0.025
pence each at a premium of 25 pence per share.
On 25 May 2022 there was an exercise of options over 12,500
Ordinary shares of 0.025 pence each.
Reconciliation of movements during the year:
Number
At 1 July 2021 278,015,926
Issue of shares 26,000,000
Exercise of share options 12,500
At 30 June 2022 304,028,426
-------------
Reserves of the Company represent the following:
Share capital - Shares in the Company held by shareholders at a
proportional level with equal voting rights per share.
Share premium - Excess over share capital of any
investments.
Retained earnings - This comprises the accumulated trading
results of the Group.
Share-based payment reserve - This reserve comprises the fair
value of options share rights recognised as an expense. Upon
exercise of options or performance share rights, any proceeds
received are credited to share capital .
7. Share options
Group & Company Number of share Weighted average
options exercise price
30 June 30 June 30 June 30 June
2022 2021 2022 2021
Number Number GBP GBP
Outstanding at 1 July 2021 729,467 287,440 0.5071 0.0010
Granted - 2,049,275 - 0.2191
Forfeited (497,186) (204,808) 0.5755 0.3355
Lapsed - (80,000) - 0.0010
Exercised (12,500) (1,322,440) 0.0003 0.0080
Outstanding at 30 June
2022 219,781 729,467 0.3997 0.5071
----------- ------------- --------- ---------
Exercisable at 30 June - - - -
2022
----------- ------------- --------- ---------
12,500 options were exercised during the year.
The options outstanding at 30 June 2022 had an exercise price
ranging from GBP0.00025 to GBP0.70 and a remaining contractual life
of 1 year and 9 months. The options exist at 30 June 2022 across
the following share option schemes:
Number Exercise Fair value Vesting
of shares price per of scheme period
share (GBP)
Options issued in April
2021 104,174 0.00025 215,449 1 year
SAYE scheme commenced in
March 2021 138,608 0.70 368,211 3 years
------------ ------------
242,782 583,660
------------ ------------
The fair value of the scheme is being expensed over the vesting
period. All share options expire 10 years after the date of
issue.
Group Company
30 June 30 June 30 June 30 June
2022 2021 2022 2021
GBP'000 GBP'000 GBP'000 GBP'000
Expenses recognised in
the year
Arising from equity settled
share-based payment transactions 231 1,367 87 1,238
---------- ---------- ---------- ----------
8. Annual Report & Accounts
The Company's Annual Report and Accounts for the year ended 30
June 2022 will be sent to shareholders on 28 November 2022 and is
available on the Company's website www.abingdonhealth.com along
with the Company's Notice of Annual General Meeting, which was sent
to shareholders on 23 November 2022.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FR PPGRPGUPPPWW
(END) Dow Jones Newswires
November 24, 2022 02:00 ET (07:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2023 to Apr 2024
